Background
Materials and methods
Patients and samples
Isolation of cfDNA from plasma
Determination of cfDNA fragment size and cfDNA level
Statistical analysis
Results
Patient characteristics
Variable | All patients (n = 61) |
---|---|
Median age | 64 (41–81) |
Sex | |
Male | 35 (57%) |
Female | 26 (43%) |
Median tumor size (mm) | 37 (11–100) |
Median CA 19-9 levels | 385.5 (5–102041) |
CA 19-9 | |
< 37U/mL | 13 (21%) |
≥ 37U/mL | 47 (77%) |
Missing data | 1 (2%) |
Tumor location | |
Pancreas head | 34 (56%) |
Pancreas body | 4 (7%) |
Pancreas tail | 13 (21%) |
Multiple | 10 (16%) |
T-stage | |
T2 | 11 (18%) |
T3 | 15 (25%) |
T4 | 25 (41%) |
TX | 2 (3%) |
Missing data | 8 (13%) |
Clinical stage | |
Stage III | 6 (10%) |
Stage IV | 55 (90%) |
Metastatic location | |
Liver | 25 (41%) |
Lung | 4 (7%) |
Multiple | 16 (26%) |
Other | 6 (10%) |
Missing data | 10 (16%) |
N-stage | |
N0 | 14 (23%) |
N1 | 25 (41%) |
NX | 21 (34%) |
Missing data | 1 (2%) |
ECOG status | |
0 | 13 (21%) |
1 | 34 (56%) |
2 | 10 (16%) |
Missing data | 4 (7%) |
First-line treatment | |
Gemcitabine | 6 (10%) |
FOLFIRINOX | 30 (49%) |
Nab-Paclitaxel + | 25 (41%) |
Gemcitabine | |
Second-line treatment | |
Yes | 17 (28%) |
No | 44 (72%) |
Prior anti-cancer surgery | |
Yes | 9 (15%) |
No | 51 (84%) |
Missing data | 1 (2%) |
Measurements of cfDNA fragment size and cfDNA level
Changes in cfDNA fragment size and cfDNA levels during therapy
Survival analyses
Parameter | Progression-free survival | Overall survival | ||
---|---|---|---|---|
Hazard ratio (95% CI) | p-value | Hazard ratio (95% CI) | p-value | |
cfDNA fragment size B1 (continuous) | 0.913 (0.865–0.962) |
0.001
| 0.897 (0.848–0.949) |
< 0.001
|
cfDNA fragment size B1 (> 167 bp vs ≤ 167 bp) | 0.409 (0.225–0.744) |
0.003
| 0.394 (0.220–706) |
0.002
|
cfDNA level B1 (continuous) | 1.002 (1.001–1.003) |
0.001
| 1.002 (1.001–1.003) |
0.001
|
cfDNA level B1 (> median vs ≤ median) | 3.773 (2.009–7.084) |
< 0.001
| 2.418 (1.350–4.329) |
0.003
|
Combination cfDNA fragment size and cfDNA levels |
< 0.001
|
0.002
| ||
0 markersa | Reference | Reference | ||
1 marker | 2.825 (1.275–6.258) | 2.032 (0.943–4.379) | ||
2 markers | 4.476 (2.139–9.364) | 3.326 (1.695–6.526) | ||
CA 19-9 (< 37U/mL vs ≥ 37U/mL) | 0.665 (0.319–1.385) | 0.276 | 0.854 (0.412–1.771) | 0.672 |
cfDNA fragment size B2 (continuous) | 0.935 (0.860–1.017) | 0.116 | 0.981 (0.899–1.070) | 0.662 |
cfDNA fragment size B2 (> 167 bp vs ≤ 167 bp) | 0.498 (0.245–1.011) | 0.054 | 0.841 (0.413–1.715) | 0.635 |
cfDNA levels B2 (continuous) | 1.061 (1.028–1.095) |
< 0.001
| 1.062 (1.026–1.099) |
0.001
|
cfDNA levels B2 (> median vs ≤ median) | 1.626 (0.786–3.365) | 0.190 | 1.412 (0.664–3.002) | 0.371 |
Age at diagnosis | 1.003 (0.973–1.035) | 0.833 | 0.990 (0.957–1.023) | 0.539 |
Sex (male vs female) | 1.194 (0.688–2.070) | 0.529 | 1.194 (0.671–2.124) | 0.546 |
Center (SUH vs HUH) | 2.176 (1.153–4.105) |
0.016
| 2.213 (1.130–4.337) |
0.021
|
Tumor size (mm) | 1.030 (1.012–1.049) |
0.001
| 1.021 (1.001–1.041) |
0.042
|
Tumor location | 0.075 | 0.075 | ||
Pancreas head | Reference | Reference | ||
Pancreas body | 0.616 (0.182–2.088) | 0.657 (0.197–2.195) | ||
Pancreas tail | 2.314 (1.165–4.596) | 2.239 (1.125–4.458) | ||
Multiple | 1.135 (0.531–2.425) | 1.581 (0.732–3.434) | ||
T-stage | 0.342 | 0.350 | ||
T2 | Reference | Reference | ||
T3 | 1.116 (0.471–2.645) | 0.922 (0.367–2.318) | ||
T4 | 0.664 (0.314–1.403) | 0.603 (0.281–1.294) | ||
Clinical stage (Stage IV vs Stage III) | 2.147 (0.836–5.515) | 0.112 | 1.829 (0.715–4.678) | 0.207 |
Metastatic location | 0.457 | 0.735 | ||
Liver | Reference | Reference | ||
Lung | 0.382 (0.113–1.288) | 0.590 (0.195–1.781) | ||
Multiple | 0.726 (0.271–1.944) | 0.767 (0.262–2.240) | ||
Other | 0.841 (0.439–1.610) | 0.740 (0.366–1.496) | ||
N-stage (N1 vs N0) | 1.745 (0.760–4.006) | 0.189 | 1.566 (0.703–3.488) | 0.273 |
ECOG performance status |
0.003
|
< 0.001
| ||
0 | Reference | Reference | ||
1 | 1.656 (0.809–3.389) | 1.634 (0.782–3.415) | ||
2 | 5.057 (1.932–13.235) | 6.810 (2.537–18.277) | ||
First-line treatment |
< 0.001
|
< 0.001
| ||
FOLFIRINOX | Reference | Reference | ||
Gemcitabine | 14.760 (4.874–44.697) | 15.099 (4.951–46.047) | ||
Nab-Pac + gemcitabine | 2.796 (1.481–5.280) | 3.201 (1.665–6.155) | ||
Second-line treatment (yes vs no) | 0.822 (0.453–1.490) | 0.519 | 0.494 (0.255–0.955) |
0.036
|
Prior anti-cancer surgery (yes vs no) | 0.601 (0.287–1.260) | 0.178 | 0.722 (0.324–1.612) | 0.427 |
Parameter | Progression-free survival | Overall survival | ||
---|---|---|---|---|
Hazard ratio (95% CI) | p-value | Hazard ratio (95% CI) | p-value | |
cfDNA level B1 (> median vs ≤ median) | 3.049 (1.398–6.649) | 0.005 | 2.236 (1.089–4.590) | 0.028 |
CA 19-9 (< 37U/mL vs ≥ 37U/mL) | n.s. | 0.345 (0.148–0.804) | 0.014 | |
ECOG performance status | 0.043 | 0.011 | ||
0 | Reference | Reference | ||
1 | 1.122 (0.486–2.589) | 1.149 (0.540–2.446) | ||
2 | 3.108 (1.066–9.056) | 4.066 (1.443–11.461) | ||
First line treatment | 0.003 | < 0.001 | ||
FOLFIRINOX | Reference | Reference | ||
Gemcitabine | 7.765 (2.313–26.068) | 12.064 (3.385–42.996) | ||
Nab-Pac + gemcitabine | 2.021 (1.002–4.076) | 2.901 (1.411–5.965) |